Almost no new therapies have succeeded in extending patient survival in GBM in the last 20 years, and the field is littered with drugs that have failed despite promising early data. But researchers soldier on with new molecular targets and therapeutic modalities.
Sword Health’s $40 million funding round was led by General Catalyst. In total, the company has raised $300 million. The most recent round brings its…
Draig Therapeutics’ lead drug is designed to safely target the AMPA receptor as a way of mediating the interplay between two neurotransmitters whose imbalance is…
Patient engagement is a clinical necessity in behavioral healthcare. Mental health treatment requires long-term commitment, consistent communication and deep trust between providers and patients.
Despite their necessity, beds and surfaces do not always receive proportional attention and innovation — even as the risks associated with prolonged bed rest remain…
Riverside Health is reporting an increase in revenue and net margins as a result of adopting Abridge’s ambient AI technology. The tool listens to doctor-patient…
Those who recognize that AI governance is an innovation enabler will be able to align business priorities and AI investments — and make smarter decisions…
Bringing together healthcare futurists, novel employers, payers, providers, investors and entrepreneurs to transform digital health.
When you equip patients with a deeper understanding of their bodies, they are better prepared to act on medical advice.
Ultimately, the benefits of establishing a data-driven culture reach far beyond improved analytics. It enables a smarter, faster, and more inclusive decision-making process that leads…
Gilead Sciences drug lenacapavir, brand name Yeztugo, is now approved for HIV pre-exposure prophylaxis. The twice injectable medication is hoped to improve uptake and adherence…
